# A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer

> **NCT02429843** · PHASE1 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 16 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** TRC105

## Key facts

- **NCT ID:** NCT02429843
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-02
- **Primary completion:** 2018-12
- **Final completion:** 2019-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2021-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02429843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02429843, "A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02429843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*